The study represents a significant breakthrough in understanding the potential for reversing and measuring epigenetic changes associated with coronary heart disease after therapeutic intervention June 13, 2023 09:01 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a […]

PrecisionCHD™ is the First Integrated Epigenetic-Genetic-Based Blood Test for the Early Detection of Coronary Heart Disease CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced the launch of PrecisionCHD™, an integrated epigenetic-genetic blood test […]